An altered herpes virus is being tested in mesothelioma patients, and the results show that it can stabilize the growth of mesothelioma tumors. Half of the patients given the virus responded to the treatment, which is very promising. Thirteen patients were injected with a version of HSV (herpes causing virus)[…]
Pleural Mesothelioma
Reducing UHRF1 Could Lengthen Mesothelioma Sufferers’ Lives
The protein UHRF1 could help people survive pleural mesothelioma. Research from the National Cancer Institute found this protein. The protein is encoded by the gene with the same name. Researchers in the study believe that it could cause the growth and spread of mesothelioma. The information needs to be confirmed[…]
A New T-Cell Treatment is Being Tested on Mesothelioma Patients
A new clinical trial at the Memorial Sloan Kettering Cancer Center is recruiting patients for a pleural mesothelioma study. The treatment involves T-cell therapy and is a very promising treatment for mesothelioma sufferers. The reason the study is being done is ATA2271, which is known as CAR T-cell therapy, was[…]
Mesothelin-targeted CAR T-cell Therapy in Patients With Mesothelioma
This study will test the safety of MSLN-targeted CAR-T cells at different doses to find the safest dose to give to people with MPM. The researchers want to see what effects, if any, the study treatment has on people with this type of cancer. This study is the first time that an MSLN-targeted CAR-T cell treatment with an anti-PD1 component is being given to people.
Opdivo and Yervoy Have Been Fully Approved for Treating Mesothelioma
A new treatment has been approved for mesothelioma by the Food and Drug Administration (FDA). The treatment uses a combination of Opdivo (nivolumab) and Yervoy (ipilimumab), which are immunotherapy drugs created by Bristol-Myers Squibb. It is the first new drug combination approved for mesothelioma in 16 years. The most recent[…]
Mesothelioma Trial Involving UV1 Cancer Vaccine and Immunotherapy
A new mesothelioma clinical trial is taking place in Oslo, Norway. The trial is looking at the UV1 cancer vaccine alongside immunotherapy. The vaccine is a peptide-based drug that activates a T-cell response, allowing the immunotherapy drugs to work better. This will be the first time that UV1 is being[…]
A Two-part Study to Characterize Drug-Drug Interaction Effects on Steady-State Pharmacokinetics of Oral Tazemetostat
This is a phase I, multi-center, open-label, multi-dose, two-part PK and safety study to characterize the DDI potential of oral Tazemetostat.
Quinacrine has Anti-Cancer Effects on Mesothelioma Cells
Pleural mesothelioma is a devastating cancer of the mesothelium, which is a lining of different organs. The most common type of mesothelioma is pleural, which affects the lining of the lungs while the second most common is peritoneal, which surrounds the lining of the abdomen. New treatments are constantly being[…]
Poly-ICLC (Hiltonol®) Vaccine In Malignant Pleural Mesothelioma
Primary Outcome Measures The probability of rejecting the investigational treatment is at least 81%, if the DLT rate is greater than 33% and the probability of accepting the treatment is at least 71% if the DLT rate is less than a safe level of 17%. [ Time Frame: up to 27 days ] Safety[…]
SAKK 17/18 (ORIGIN) MPM & NSCLC >1st Line Gemci & Atezo Ph II
Primary Outcome Measures Primary endpoint for cohort 1: Objective response rate (ORR) according to RECIST 1.1 [ Time Frame: At the date of tumor assessment according to RECIST 1.1, assessed up to 2 years after registration ] ORR according to RECIST 1.1 is defined as the proportion of patients, whose best overall response is[…]
Skip to content